← back to search

James Talks

University of Birmingham · GB
Area of research
Ophthalmology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Medicine, Macular degeneration, Ophthalmology, Visual acuity, Aflibercept, and Population.
h-index
citations
1,729
works
11
NIH funding
primary concept
email

Recent publications

Improving Clinical Management of Diabetic Macular Edema: Insights from a Global Survey of Patients, Healthcare Providers, and Clinic Staff
Ophthalmology and Therapy 2024cited by 7position: middledoi
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohort
Eye 2024cited by 1position: middledoi
Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations
Eye 2021cited by 48position: middledoi
Defining Nonadherence and Nonpersistence to Anti–Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration
JAMA Ophthalmology 2021cited by 43position: middledoi
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial
The Lancet 2020cited by 224position: middledoi
Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration
Ophthalmology 2020cited by 196position: middledoi
Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
BMC Ophthalmology 2020cited by 137position: middledoi
Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
British Journal of Ophthalmology 2020cited by 71position: middledoi
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial
The Lancet 2017cited by 382position: middledoi
Defining response to anti-VEGF therapies in neovascular AMD
Eye 2015cited by 342position: middledoi
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES
Retina 2015cited by 278position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Tien Yin Wong · Neuroscience Research Australia5 papers (2020–2024)Robert P. Finger · London School of Hygiene & Tropical Medicine5 papers (2020–2024)Richard Gale · York Teaching Hospital NHS Foundation Trust4 papers (2015–2024)Jean‐François Korobelnik · Université de Bordeaux4 papers (2015–2024)Paul Mitchell · The University of Sydney4 papers (2015–2021) · 3 papers (2020–2024)Vincent Daïen · The University of Sydney3 papers (2020–2021)Anat Loewenstein · Westmead Hospital3 papers (2020–2024) · 2 papers (2020–2021) · 2 papers (2020–2020)Tariq Aslam · University of Manchester2 papers (2021–2024)Winfried M. K. Amoaku · University of Nottingham2 papers (2015–2024)Laurent Kodjikian · Université Claude Bernard Lyon 12 papers (2021–2024) · 2 papers (2020–2021)Francisco J. Rodríguez · University of Colorado Denver1 papers (2021–2021) · 1 papers (2024–2024) · 1 papers (2024–2024)Sobha Sivaprasad · UK Biobank1 papers (2015–2015)Praveen J. Patel · UK Biobank1 papers (2024–2024)Rohini Kumar Verma · Novartis (Switzerland)1 papers (2021–2021)